Pharma Or Biotech – Which Innovates Better?
This article was originally published in The Pink Sheet Daily
Pfizer Incubator head, CEOs from Acadia, AviaraDX, BIOCOM and Regulus recently had a roundtable discussion with "The Pink Sheet" DAILY.
You may also be interested in...
Firms will co-develop microRNA targeted therapeutics in inflammation and immunology.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.